Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Phase 1 Completed 119 enrolled Amgen

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with either FOLFIRI or FOLFOX4 chemotherapy regimens. This is a Phase 1b clinical study.

Timeline

Start: 2004-12
Primary completion: 2010-04
Completion: 2011-12

Publications

Tebbutt N, Kotasek D, Burris HA, Schwartzberg LS, Hurwitz H, Stephenson J, Warner DJ, Chen L, Hsu CP, Goldstein D. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015 May;75(5):993-1004. doi: 10.1007/s00280-015-2694-y. Epub 2015 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Panitumumab	Monoclonal antibody	6 mg/kg	Intravenous
Subject	motesanib	Small molecule	50 mg	Oral
Subject	motesanib	Small molecule	75 mg	Oral
Subject	motesanib	Small molecule	100 mg	Oral
Subject	motesanib	Small molecule	125 mg	Oral
Background	Irinotecan	Small molecule	—	—
Background	Leucovorin	Small molecule	100 mg/m2	Intravenous
Background	Leucovorin	Small molecule	200 mg/m2	Intravenous
Background	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	600 mg/m2	Intravenous

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications